XL092 and Cemiplimab in BRAF WT Thyroid Cancer

NCT06902376 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Thyroid Cancer
Thyroid Cancer
BRAF Mutation-Related Tumors

Interventions

BIOLOGICAL: Cemiplimab
DRUG: XL092

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]